Stocks · News reference
8-K filing — Outlook Therapeutics, Inc. (OTLK)
Filed: 2026-09-30 AccNo: 0001104659-26-112356 Size: 189 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10.5
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and raises the price target from $10 to $10.5.
Outlook Therapeutics Announces Appointment Of Kevin Lundquist As CFO Effective September 1